{"name":"Siegfried Holding","slug":"siegfried","ticker":"SFZN.SW","exchange":"SIX Swiss Exchange","domain":"siegfried.ch","description":"Siegfried Holding AG, together with its subsidiaries, engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide. It offers drug substances, including exclusive synthesis that manufactures custom APIs. The company also offers an API portfolio, including non-exclusive APIs and pharma-grade substances that focus on anesthetics, pain and addiction treatment applications, and central nervous and respiratory diseases, as well as caffeine for human health and nutrition. In addition, it offers drug products, including steriles, which includes fill and finish in vials, ampoules, cartridges, and pre-filled syringes; ophthalmics, such as sterile ointments, gels, and suspensions and solutions; inhalation products, including capsules in medical devices for inhalation applications; oral solid dosage forms, which includes tablets and capsules; and viral vectors, such as AAV and lentiviruses for gene therapy. Further, the company pr","hq":"Zofingen, Switzerland","founded":1909,"employees":"3891","ceo":"Wolfgang Wienand","sector":"CDMO / Contract Manufacturing","stockPrice":80.15,"stockChange":-0.05,"stockChangePercent":-0.06,"marketCap":"$4.5B","metrics":{"revenue":1695590618.641843,"revenueGrowth":5,"grossMargin":26.7,"rdSpend":0,"netIncome":215370773.1238784,"cash":132542042.441,"dividendYield":0.5,"peRatio":20.9,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Lynparza patent cliff ($1.4B at risk)","drug":"Lynparza","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Siegfried Holding Reports Strong Q4 2023 Earnings","summary":"Siegfried Holding reported strong Q4 2023 earnings, driven by increased demand for its contract manufacturing services.","drugName":"","sentiment":"positive"},{"date":"2023-09-01","type":"deal","headline":"Siegfried Holding Partners with Leading Biotech Company","summary":"Siegfried Holding announced a partnership with a leading biotech company to develop and manufacture a novel API.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiVEFVX3lxTE1BUjRzMEJydmtPR2tLT1NDYzJiWklSTnAwUVhxR1pTdHVnLV9QSXdhb2cyNHdrSXplSzVvRG12cklwa3RvejdOVVE1czNfb3lTSkRtTw?oc=5","date":"2024-04-10","type":"pipeline","source":"Yahoo Finance Australia","summary":"Sandoz Group AG (SDZ.SW) stock price, news, quote and history - Yahoo Finance Australia","headline":"Sandoz Group AG (SDZ.SW) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWEFVX3lxTE1LNkJna2JQemVrQnRfd2lRT01Zb2tGUkp4MndNLTVtRVBsMV9GeHd6WDNjblNyZkl0UG5wTnN4TGdRclNkRThORWRPdUtybVYwTjFTaVJFRlk?oc=5","date":"2023-04-25","type":"pipeline","source":"Yahoo! Finance Canada","summary":"H. Lundbeck A/S (HLUN-B.CO) Stock Price, News, Quote & History - Yahoo! Finance Canada","headline":"H. Lundbeck A/S (HLUN-B.CO) Stock Price, News, Quote & History - Yahoo! Finance Canada","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWEFVX3lxTE9KMURvN085VDFKLUlrR1luSE1mUlRvUEM4cXJsT1pCeUtuYUtIem9LX05jRVJLZGJ1UEhzZDJ5ejdJRnUzeXlrZGNLZ3VpcmdJSjRjR1hfMzA?oc=5","date":"2017-09-27","type":"pipeline","source":"TradingView","summary":"SFZN Stock Price and Chart — SIX:SFZN - TradingView","headline":"SFZN Stock Price and Chart — SIX:SFZN","sentiment":"neutral"}],"patents":[{"drugName":"Lynparza","drugSlug":"olaparib","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":1400000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Lonza Group AG","Catalent, Inc.","Evonik Industries AG"],"therapeuticFocus":["Oncology","Rare Diseases"],"financials":{"source":"yahoo_finance","revenue":1695590639.0732,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":1695590639.0732},{"period":"2024-12-31","value":1653117679.1654},{"period":"2023-12-31","value":1623646723.9412},{"period":"2022-12-31","value":1570045059.3764}],"grossProfit":452036107.4412,"grossProfitHistory":[{"period":"2025-12-31","value":452036107.4412},{"period":"2024-12-31","value":420192560.9086},{"period":"2023-12-31","value":409148135.5984},{"period":"2022-12-31","value":407209710.622}],"rdSpend":58972557.4836,"rdSpendHistory":[{"period":"2025-12-31","value":58972557.4836},{"period":"2024-12-31","value":52502202.177},{"period":"2023-12-31","value":56828541.9794},{"period":"2022-12-31","value":55132739.365}],"sgaSpend":126136812.0842,"operatingIncome":276161711.147,"operatingIncomeHistory":[{"period":"2025-12-31","value":276161711.147},{"period":"2024-12-31","value":248700690.648},{"period":"2023-12-31","value":215380978.5866},{"period":"2022-12-31","value":292394424.1246}],"netIncome":215370762.9082,"netIncomeHistory":[{"period":"2025-12-31","value":215370762.9082},{"period":"2024-12-31","value":204395293.4272},{"period":"2023-12-31","value":144007864.4852},{"period":"2022-12-31","value":199831439.102}],"eps":3.84,"epsHistory":[{"period":"2025-12-31","value":3.84},{"period":"2024-12-31","value":3.69},{"period":"2023-12-31","value":2.622},{"period":"2022-12-31","value":3.628}],"cash":131631570.1036,"cashHistory":[{"period":"2025-12-31","value":131631570.1036},{"period":"2024-12-31","value":49489854.0088},{"period":"2023-12-31","value":71973285.2074},{"period":"2022-12-31","value":116820113.3834}],"totalAssets":2749987838.5714,"totalLiabilities":1310145431.2824,"totalDebt":null,"equity":1440568997.4152,"operatingCashflow":291349871.0082,"operatingCashflowHistory":[{"period":"2025-12-31","value":291349871.0082},{"period":"2024-12-31","value":215521444.16459998},{"period":"2023-12-31","value":266384029.95839998},{"period":"2022-12-31","value":181762457.932}],"capex":-295576607.9462,"capexHistory":[{"period":"2025-12-31","value":-295576607.9462},{"period":"2024-12-31","value":-230934348.9506},{"period":"2023-12-31","value":-175063526.82119998},{"period":"2022-12-31","value":-147115984.6384}],"freeCashflow":-4226736.938,"dividendsPaid":-21239672.3534,"buybacks":0,"employees":3891,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":80.15,"previousClose":80.2,"fiftyTwoWeekHigh":101.6,"fiftyTwoWeekLow":68.5,"fiftyTwoWeekRange":"68.5 - 101.6","fiftyDayAverage":78.43,"twoHundredDayAverage":80.96,"beta":0.77,"enterpriseValue":5084959349.401088,"forwardPE":17.6,"priceToBook":3.11,"priceToSales":2.64,"enterpriseToRevenue":3,"enterpriseToEbitda":12.92,"pegRatio":2.62,"ebitda":393496449.5454784,"ebitdaMargin":23.2,"freeCashflow":-26613757.6717,"operatingCashflow":291349881.2238784,"totalDebt":734507276.96,"debtToEquity":51,"currentRatio":2,"returnOnAssets":6.8,"returnOnEquity":16,"analystRating":"1.9 - Buy","recommendationKey":"buy","numberOfAnalysts":10,"targetMeanPrice":105,"targetHighPrice":126,"targetLowPrice":85,"dividendRate":0.4,"payoutRatio":0.1,"fiveYearAvgDividendYield":0.72,"exDividendDate":1777334400,"insiderHeldPercent":13.2,"institutionHeldPercent":54.6,"sharesOutstanding":43808440,"floatShares":39796901,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":3.84,"epsForward":4.55,"revenuePerShare":30.34,"bookValue":25.75,"officers":[{"age":58,"name":"Mr. Marcel  Imwinkelried","title":"CEO & COO Drug Products ad interim"},{"age":54,"name":"Dr. Reto  Suter Ph.D.","title":"Chief Financial Officer"},{"age":null,"name":"Mr. Stefan  Randl","title":"Interim Chief Operating Officer Drug Substances & Chief Scientific Officer"},{"age":null,"name":"Dr. Luca Dalla Torre","title":"Chief Legal & Sustainability Officer"},{"age":null,"name":"Mr. Peter  Stierli","title":"Head of Corporate Communications"},{"age":43,"name":"Ms. Olesia  Silanteva","title":"Chief Human Resources Officer"},{"age":null,"name":"Mr. Enno  Schweinberger Ph.D.","title":"Head Global Quality Management DS - Zofingen"},{"age":null,"name":"Beatrice  Harder","title":"Head Regulatory Affairs - Site Zofingen"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"","website":"https://www.siegfried.ch","phone":"41 62 746 1111"}}